(0.23%) 5 143.25 points
(0.22%) 38 527 points
(0.32%) 17 902 points
(-0.45%) $83.47
(1.98%) $1.961
(-0.02%) $2 346.70
(0.28%) $27.61
(0.84%) $929.85
(-0.22%) $0.933
(-0.31%) $10.99
(-0.30%) $0.798
(1.16%) $92.94
Live Chart Being Loaded With Signals
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation...
Stats | |
---|---|
今日成交量 | 58 129.00 |
平均成交量 | 162 320 |
市值 | 73.84M |
EPS | $0 ( 2024-04-16 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.240 |
ATR14 | $0.0200 (1.49%) |
Connect Biopharma 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-14.50 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-14.50 |
Financial Reports:
No articles found.
Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。